Avammune Therapeutics raises $12 million in Series A funding round co-led by Capital 2B and Shastra VC. The funds will advance its pipeline targeting the innate immune system.
Amount Raised
$12 Million
Round Type
Series A
PhiladelphiaBiotechnologyHealth CareTherapeuticsInvestors
Description
Avammune Therapeutics has secured $12 million in a Series A financing round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I. The proceeds will be utilized to accelerate its proprietary pipeline targeting the innate immune system. The company is focused on developing small molecules for cancer and autoimmune disorders. Its lead asset is an ENPP1 inhibitor with demonstrated anti-tumor efficacy.
Quick answer
Avammune Therapeutics raised $12 Million in a Series A round, dated May 7, 2025. Investors: Shastra VC, Ivycap Ventures, 1Crowd, Capital 2B and Kotak Lifesciences Fund I. Avammune Therapeutics is based in Philadelphia, Pennsylvania, United States.
- How much did Avammune Therapeutics raise?
- Avammune Therapeutics raised $12 Million in a Series A round on May 7, 2025.
- Who invested in Avammune Therapeutics?
- Shastra VC, Ivycap Ventures, 1Crowd, Capital 2B and Kotak Lifesciences Fund I are named as investors in this round.
- What does Avammune Therapeutics do?
- Avammune Therapeutics is a biopharmaceutical company founded in 2020 that focuses on discovering small molecule medicines targeting the innate immune system for cancer and autoimmune disorder treatments.
- Where is Avammune Therapeutics based and how big is it?
- Avammune Therapeutics is based in Philadelphia, Pennsylvania, United States. Fundz records about 11 employees.
- Who are the decision-makers at Avammune Therapeutics?
- Fundz holds 1 contact at Avammune Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Avammune Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Actio Biosciences raised $66M (Series B) on June 18, 2025.
- Canton Strategic Holdings, Inc. raised $2.5M (Seed) on June 13, 2025.
- Arialys Therapeutics raised $15M on June 13, 2025.
- ADC Therapeutics raised $100M (Private Equity) on June 12, 2025.
- Ensho Therapeutics raised $23M on June 12, 2025.
- Elkedonia raised $13M (Seed) on June 11, 2025.
Who to call at Avammune Therapeutics, and when
A new round usually means Avammune Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Avammune Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Avammune Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Avammune Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Avammune Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAvammune Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.